Inve India ▾

IPCA Laboratories share price & results

IPCA Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Mumbai-based pharma maker of branded/generic formulations and APIs, exporting to 100+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue2,788 ₹ crore+20.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin24.0 %+6.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit424 ₹ crore+82.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity18.31 %+3.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin5.06 %−1.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)10.57 %−8.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 6 judged targets kept · 15 open · verdicts reflect calls analysed to Q1 FY27.

IPCA Laboratories Limited management guidance track record on Inve: 21 targets tracked across analysed earnings calls (3 achieved, 3 missed, 15 open).

TargetOriginal wordingSaidLatest callVerdict
R&D Spend as % of RevenueMove to around 4%
Call transcript, Q3 FY25 · 13 Feb 2025		Q3 FY25Q1 FY27:No update provided on R&D spend as a percentage of revenue. Only capex for R&D facilities mentioned.
Call transcript, Q1 FY27 · 14 Aug 2026		Ghosted
ANDA Filings (Ipca)5 to 6 filings every year
Call transcript, Q3 FY25 · 13 Feb 2025		Q3 FY25Q1 FY27:Guidance revised down to '4 to 5 filings will happen every year for Ipca' from the original 5-6.
Call transcript, Q1 FY27 · 14 Aug 2026		Revised Down
Consolidated EBITDA MarginImprove by around 1% to around 20% for FY26
Call transcript, Q4 FY25 · 30 May 2025		Q4 FY25Q4 FY26:FY26 consolidated EBITDA margin reported at 20.72%, meeting the ~20% guidance.
Call transcript, Q4 FY26 · 1 Jun 2026		Achieved

Source: Inve Guidance Tracker for IPCA Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of IPCA Laboratories Limited's 21 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,938.6 −0.75% · −₹14.7

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +52.8% 1Y

₹1.4k₹1.6k₹1.8k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 16 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 14 Aug 2026

1Y: ₹1,268.7 on 24 Oct 2025 → ₹1,938.6. High ₹2,009.6 (18 Sept 2026), low ₹1,268.7 (24 Oct 2025).

Previous close
₹1,953.3
Market cap
₹50.2k Cr
52-week range
₹1,271.2 – ₹2,009.6
One year
+49.35%
Price to earnings (TTM to Jun 2026)
36.52×
Return on equity (TTM to Jun 2026)
18.31%

Overview

Symbol
NSE:IPCALAB
Exchange
NSE
Currency
INR

What IPCA Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Ipca Laboratories manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) and drug intermediates. Its domestic branded-formulations business is organised into 22 marketing divisions spanning therapy areas led by pain management, cardiovascular/anti-diabetics, anti-malarials, anti-bacterials and dermatology. It exports formulations and APIs to over 100 countries, with the API business supplying international generic-formulation manufacturers, including several multinationals. The company also runs an in-house R&D network supporting new APIs, dosage forms and drug-delivery systems.

Segments

  • Formulations
  • APIs & Intermediates
Domestic formulations market rank
16th largest in India (IQVIA MAT March 2025)
Manufacturing facilities (India)
18 works across 6 states/UTs (Madhya Pradesh, Gujarat, Maharashtra, Dadra & Nagar Haveli, Uttarakhand, Sikkim)
Countries exported to
100+
R&D centres
4 (Mumbai, Ratlam, Athal/Silvassa, Ranu/Vadodara), DSIR-recognised
Domestic marketing divisions
22
Branded formulation portfolio
~174 brands; 6 feature among India's top 300 selling formulation brands
Founded 1949Headquarters Mumbai, Maharashtra, IndiaEmployees 18,043 (2025-03-31) Company website

How the price took the results

close before → close after

Q1 FY27
−3.5%
14 Aug
Q4 FY26
−2.2%
1 Jun
Q3 FY26
+0.7%
16 Feb
Q2 FY26
−2.9%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for IPCA Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow IPCA Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse IPCA Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.